SlideShare a Scribd company logo
1 of 36
Download to read offline
Welcome
Brent Polk, MD
SECURE-IBD REGISTRY AND
IBD PARTNERS UPDATE
Data pulled on 5/21/2020. Updated data from SECURE-IBD can be viewed at covidibd.org. Additional information
on IBD Partners is available at ccfa.med.unc.edu
Michael Kappelman MD, MPH (University of North Carolina at Chapel Hill)
Erica Brenner, MD (University of North Carolina at Chapel Hill)
Jean-Frederic Colombel, MD (Icahn School of Medicine at Mount Sinai, New York)
Ryan Ungaro, MD MS (Icahn School of Medicine at Mount Sinai, New York)
Purpose
• To rapidly define the impact of coronavirus on patients with IBD
and evaluate how factors such as age, comorbidities, and IBD
treatments affect coronavirus outcomes.
• To openly share findings with the IBD community including the
outcomes of COVID-19 broken down by patient age, gender, IBD
treatments, and other factors.
Database
• Web-based survey filled out by IBD health
care providers from across the globe
– Collects data on patient location,
demographics, IBD characteristics,
comorbidities, and coronavirus outcomes
• Data stored on secure, encrypted servers
at the University of North Carolina
• All data are de-identified, in accordance
with HIPAA Safe Harbor standards
Website
• Landing page
• Project information and FAQs
• Access to the database
• Facilitate rapid sharing of data
• Link to patient/provider
resources
• Acknowledge partnering
organizations
Why is the registry important for patients?
• SECURE-IBD will help
answer important questions
about coronavirus risk for
patients with IBD,
particularly regarding IBD
medications and
characteristics
• The online format allows for
rapid and free data sharing
• 1170 reported cases
• 42 different countries
• Median age 45
• 52% Male
• 56% Crohn’s disease
Preliminary data (5/18/20)
SECURE-IBD: an International Effort
SECURE-IBD Cases over time
Outcomes by age
Outcomes by comorbidities
Outcomes by medication class
SECURE-IBD Take Away Points
• Overall low mortality ~ 4%
– No deaths in patients <20 years of age
• Systemic steroids appear to be a risk factor for worse outcomes of
COVID-19
• Anti-TNF biologic therapy appears to be safe
• Need more data and further analyses to fully evaluate safety of
other classes of medications
• In general, data support current recommendations to continue IBD
therapy in healthy patients
– Discuss with physician temporary holding of medications for infected pts
Our Partners:
Thank you!
And many more organizations and pharmaceutical partners listed at https://covidibd.org/our-partners/
SECURE-IBD has been funded, in part,
by the Helmsley Charitable Trust,
multi-pharmaceutical sponsorship,
and NC TraCS
COVID-19 and Inflammatory Bowel Disease:
IBD Partners Patient Powered Research Network
Millie D. Long MD, MPH
5-20-2020
Associate Professor of Medicine
Vice-Chief for Education
Director, Gastroenterology and Hepatology Fellowship Program
Inflammatory Bowel Diseases Center
University of North Carolina-Chapel Hill
What is IBD Partners?
• Large, diverse population
Follow natural history of
disease
• Exposures, health behaviors,
outcomes
Patient generated data
• Surveys, health apps/devices,
personal health records
Include diverse data
sources
• Support a diverse array of
studies
Create widely-used
resource
• Goal of improving outcomes
Increase patient partners/
citizen scientists
Long MD, et al. Inflamm Bowel Dis. 2012 Nov;18(11):2099-106.
Who we are: Partners
IBD Patient Community
Crohn’s & Colitis Foundation
Researchers/ UNC Data
Management Center
Long MD, et al. Inflamm Bowel Dis. 2012 Nov;18(11):2099-106.
IBD Partners represents the future of IBD research
• A partnership with patients
• Internet increases participation and potentially allow previously under-represented groups to be
included
• Ability to study those questions that matter the most to patients
• Collaborative and open-access research with diverse groups of investigators participating –
including academic faculty, trainees, industry and patients
• Thus far over 50 researchers from various institutions across the country have participated
in IBD Partners research
• Collaborations with federal funding agencies
• Collaborations with industry funding for investigator initiated projects on real world data,
which is increasing recognized by the FDA
• Opportunity for large scale RCTS of modifiable factors in IBD based on data from prospective
cohorts
How it works
• Enroll IBD patients from Foundation email rosters, Foundation
web-page link, social media, walks, clinics, etc.
• Baseline survey
– Demographics, disease characteristics, medications, family history, quality
of life scales
– Disease activity instruments
• Follow-up surveys - change in treatment or health status
– Medications, surgery, disease activity
– Addition of modules - pain, fatigue, sleep, physical function, emotional
distress, social support
• Short data collection through portal, can be daily
• Syncing apps to make use of existing “big data” resources
Current IBD Partners Enrollment (>15,000!)
How it works: Patients Pose Questions
Influence IBD research by proposing, discussing, and
voting on research questions.
Examples of questions proposed by patients:
• “We should compare individuals who manage their disease with medication
and those who manage their disease with popular diets in the IBD
community, such as SCD, FODMAPS, paleo, etc.”
• “Research the validity of VSL#3 probiotic in controlling flare ups or as a
factor in remission.”
• “What is the role of stress and the stress response in autoimmunity?”
• “Compare symptoms of IBD patients who consume dairy and those who
avoid dairy.”
• How is COVID-19 affecting IBD Patients? What are the risks of COVID-19 for
IBD Patients?
COVID-19 Survey in IBD Partners
• Questions on symptoms, diagnosis, testing for COVID-19 for each
patient, as well as levels of general knowledge about resources in
their area (testing, etc.)
• Collect data on medication use, disease activity
• Understand health care utilization – access to telemedicine, issues
with obtaining medications, refills, getting to infusions, etc
• Understand level of concern in IBD patients, both for developing
COVID-19 and concerns surrounding particular medications
• Understand loss of employment, insurance due to COVID-19
• Track real time cases in states throughout the US
Goal: Report this information back to patients, in summaries and maps
available on the IBD Partners Website
Characteristics of patients (n=1439)
N (Mean) % (SD) Median IQR
Total number of patients 1439
Age (years) 49.7 15.15 49 37.0 ,62.0
Gender (% female) 1050 74.7% 0
Education (% >high school) 1308 90.9%
Race (%)
Caucasian 1269 88.2%
African American 19 1.3%
Other 151 10.5%
Current smoking (% yes) 31 2.2%
BMI 26.0 6.03 24.5 21.9 ,28.7
Disease duration (years) 21.1 13.01 18 12.0 ,28.0
Ever GI surgery (% yes) 649 46.1%
Ever GI hospitalization (% yes) 914 65.0%
Number hospitalizations 3.7 2.65 3 1.0 ,6.0
Current medications (%)
Biologic Anti-TNF 497 35.4%
Immunomodulator* 307 21.8%
Corticosteroids 110 7.8%
5-ASA 397 28.2%
Remission (sCDAI^ <150 or SCCAI ≤2) (% yes) 729 68.7%
sCDAI (median, IQR) 127.0 85.30 107 58.0 ,163.0
SCCAI (median, IQR) 2.1 1.99 2 1.0 ,3.0
Anxiety (PROMIS T score) 51.4 9.46 51.2 40.3 ,57.7
Level of Concern about COVID
How concerned are you about COVID? How concerned are you that your medications
increase your COVID risk?
Avoiding Healthcare Needs
Avoiding Environmental Factors
Telehealth and Information Sources for Patients
• 78.5% of IBD patients’ doctors offices are offering telehealth
• 42% of patients have had a telehealth visit
• Where are patients getting data about COVID-19?
– GI physicians (36.7%)
– CDC 78.4%
– News 88.0%
– Social media 37.2%
– Crohns and Colitis Foundation website 38.1%
– Other websites 25.9%
– Family/friends 34.1%
– Other 7.5%
Employment Status and Health Insurance Loss Due
to COVID-19
• Employment change due to COVID-19
– Laid off 4.7%
– Reduced hours 9.0%
– Work from home now 39.0%
– Changed jobs 0.3%
– Job responsibilities changed 6.9%
• Health insurance change
– Lost insurance 0.2%
– Change in insurance 0.4%
– Other 0.5%
Patients Reporting Sickness (n=557)
• 557 patients (38.7%) report becoming sick
• 62 patients (4.3%) tested
• 44 patients (3.1%) were in contact with someone who tested
positive
• 7 patients (0.5%) with COVID-19 confirmed by testing
• 54 patients (3.8%) stopped a IBD medication when they were sick
• Severity of illness among those who were sick
– Very mild 106 patients, 19%
– Mild 200 patients, 36%
– Moderate 212 patients, 38%
– Severe 34 patients, 6%
– Very severe 3 patients, 1%
Interactive Map of Sickness and COVID+ in the US
for IBD Patients
Medication Changes Among Those NOT Sick
(n=880)
• Have you temporarily stopped medications due to concerns for
COVID-19?
– 37 patients, 4%
• Why did you stop the medication?
– Doctor told me to (38%)
– I thought it would reduce my chances of COVID (92%)
– I thought it would make COVID infection worse (81%)
– Other (54%)
Summary
• IBD patients are extremely concerned about COVID-19 risks generally and
medication-specific risks
• Patients are avoiding many health-related activities like labs, procedures and
even infusions
• Nearly all IBD patients in this survey are self-isolating
• Less than ½ of IBD patients have accessed telehealth
• Many patients have had work-related changes, particularly working from home,
although a minority have been laid off; majority have retained health insurance
• Many patients report sickness symptoms, only a small minority have been
tested
• Some patients (~4%) have stopped medications due to concerns for COVID-19
• Continued surveys will allow us to track rates real-time across the country to
better inform the IBD community
UNC Multidisciplinary IBD Center
Thank you to our sponsors:
34
Additional support is provided through the Foundation’s
annual giving program and donors.
Learn more @ cctakesteps.org
Unite with the IBD community at
our first virtual walk!
Saturday, June 20, 2020
12:00PM to 3:00PM (ET)
Please donate today:
crohnscolitisfoundation.org/emergency

More Related Content

What's hot

Best Practices in the Management of HCV/HIV Coinfection: Optimizing Treatment...
Best Practices in the Management of HCV/HIV Coinfection: Optimizing Treatment...Best Practices in the Management of HCV/HIV Coinfection: Optimizing Treatment...
Best Practices in the Management of HCV/HIV Coinfection: Optimizing Treatment...Hivlife Info
 
7. hcv treatment for pwid final
7. hcv treatment for pwid final7. hcv treatment for pwid final
7. hcv treatment for pwid finalantoine piaton
 
Aids Care Scheme
Aids Care SchemeAids Care Scheme
Aids Care SchemeMed Bee
 
2. natural history of hepatitis c infection final
2. natural history of hepatitis c infection final2. natural history of hepatitis c infection final
2. natural history of hepatitis c infection finalantoine piaton
 
IOSR Journal of Pharmacy (IOSRPHR)
IOSR Journal of Pharmacy (IOSRPHR)IOSR Journal of Pharmacy (IOSRPHR)
IOSR Journal of Pharmacy (IOSRPHR)iosrphr_editor
 
Metabolink IRCCS Casa Sollievo della Sofferenza 14 settembre 2016
Metabolink  IRCCS Casa Sollievo della Sofferenza 14 settembre 2016Metabolink  IRCCS Casa Sollievo della Sofferenza 14 settembre 2016
Metabolink IRCCS Casa Sollievo della Sofferenza 14 settembre 2016Redazione InnovaPuglia
 
9. tackling the hepatitis c epidemic global landscape final
9. tackling the hepatitis c epidemic global landscape final9. tackling the hepatitis c epidemic global landscape final
9. tackling the hepatitis c epidemic global landscape finalantoine piaton
 
1. what is hepatitis c virus final
1. what is hepatitis c virus final1. what is hepatitis c virus final
1. what is hepatitis c virus finalantoine piaton
 
Hepatitis C Research Gaps - Graham Cooke
Hepatitis C Research Gaps - Graham CookeHepatitis C Research Gaps - Graham Cooke
Hepatitis C Research Gaps - Graham CookeReShape
 
Global health care challenges and trends_ besty
Global health care challenges and trends_ bestyGlobal health care challenges and trends_ besty
Global health care challenges and trends_ bestyBesty Varghese
 

What's hot (20)

Best Practices in the Management of HCV/HIV Coinfection: Optimizing Treatment...
Best Practices in the Management of HCV/HIV Coinfection: Optimizing Treatment...Best Practices in the Management of HCV/HIV Coinfection: Optimizing Treatment...
Best Practices in the Management of HCV/HIV Coinfection: Optimizing Treatment...
 
7. hcv treatment for pwid final
7. hcv treatment for pwid final7. hcv treatment for pwid final
7. hcv treatment for pwid final
 
Aids Care Scheme
Aids Care SchemeAids Care Scheme
Aids Care Scheme
 
Vaccinating the elderly
Vaccinating the elderlyVaccinating the elderly
Vaccinating the elderly
 
2. natural history of hepatitis c infection final
2. natural history of hepatitis c infection final2. natural history of hepatitis c infection final
2. natural history of hepatitis c infection final
 
Ats neumonia
Ats neumoniaAts neumonia
Ats neumonia
 
IOSR Journal of Pharmacy (IOSRPHR)
IOSR Journal of Pharmacy (IOSRPHR)IOSR Journal of Pharmacy (IOSRPHR)
IOSR Journal of Pharmacy (IOSRPHR)
 
Tumour Agnostic Treatments
Tumour Agnostic TreatmentsTumour Agnostic Treatments
Tumour Agnostic Treatments
 
Metabolink IRCCS Casa Sollievo della Sofferenza 14 settembre 2016
Metabolink  IRCCS Casa Sollievo della Sofferenza 14 settembre 2016Metabolink  IRCCS Casa Sollievo della Sofferenza 14 settembre 2016
Metabolink IRCCS Casa Sollievo della Sofferenza 14 settembre 2016
 
Wesat2003
Wesat2003Wesat2003
Wesat2003
 
9. tackling the hepatitis c epidemic global landscape final
9. tackling the hepatitis c epidemic global landscape final9. tackling the hepatitis c epidemic global landscape final
9. tackling the hepatitis c epidemic global landscape final
 
HPV Prevention for Cancer Survivors
HPV Prevention for Cancer SurvivorsHPV Prevention for Cancer Survivors
HPV Prevention for Cancer Survivors
 
1. what is hepatitis c virus final
1. what is hepatitis c virus final1. what is hepatitis c virus final
1. what is hepatitis c virus final
 
Hepatitis C Research Gaps - Graham Cooke
Hepatitis C Research Gaps - Graham CookeHepatitis C Research Gaps - Graham Cooke
Hepatitis C Research Gaps - Graham Cooke
 
Sexually Transmitted Infections Update
Sexually Transmitted Infections UpdateSexually Transmitted Infections Update
Sexually Transmitted Infections Update
 
Global health care challenges and trends_ besty
Global health care challenges and trends_ bestyGlobal health care challenges and trends_ besty
Global health care challenges and trends_ besty
 
03.19.21 | Updates in HIV Prevention from Virtual CROI 2021
03.19.21 | Updates in HIV Prevention from Virtual CROI 202103.19.21 | Updates in HIV Prevention from Virtual CROI 2021
03.19.21 | Updates in HIV Prevention from Virtual CROI 2021
 
Nurtritional status of plwa proposal
Nurtritional status of plwa proposalNurtritional status of plwa proposal
Nurtritional status of plwa proposal
 
International Journal of Hepatology & Gastroenterology
International Journal of Hepatology & GastroenterologyInternational Journal of Hepatology & Gastroenterology
International Journal of Hepatology & Gastroenterology
 
feasibility study
feasibility studyfeasibility study
feasibility study
 

Similar to Updates on COVID-19 Research: SECURE-IBD & IBD Partners

Covid 19 vaccination-isop_june_2021
Covid 19 vaccination-isop_june_2021Covid 19 vaccination-isop_june_2021
Covid 19 vaccination-isop_june_2021Azeem Majeed
 
Designing Causal Inference Studies Using Real-World Data
Designing Causal Inference Studies Using Real-World DataDesigning Causal Inference Studies Using Real-World Data
Designing Causal Inference Studies Using Real-World DataInsideScientific
 
Determining Prognosis in Cancer and Non-Cancer Diagnosis
Determining Prognosis in Cancer and Non-Cancer DiagnosisDetermining Prognosis in Cancer and Non-Cancer Diagnosis
Determining Prognosis in Cancer and Non-Cancer DiagnosisVITAS Healthcare
 
Adherence to Antiretroviral Therapy among HIVPositive Patients in Central Hos...
Adherence to Antiretroviral Therapy among HIVPositive Patients in Central Hos...Adherence to Antiretroviral Therapy among HIVPositive Patients in Central Hos...
Adherence to Antiretroviral Therapy among HIVPositive Patients in Central Hos...Efe Clement Abel
 
Weitzman ECHO COVID-19: Caring for Key Populations
Weitzman ECHO COVID-19: Caring for Key PopulationsWeitzman ECHO COVID-19: Caring for Key Populations
Weitzman ECHO COVID-19: Caring for Key PopulationsCHC Connecticut
 
PPT PROJECT FINAL-1-1.pptx
PPT PROJECT FINAL-1-1.pptxPPT PROJECT FINAL-1-1.pptx
PPT PROJECT FINAL-1-1.pptxBindu238662
 
EVIDENCE-BASED CARESHEETAuthorsHillary Mennella, DNP
EVIDENCE-BASED CARESHEETAuthorsHillary Mennella, DNPEVIDENCE-BASED CARESHEETAuthorsHillary Mennella, DNP
EVIDENCE-BASED CARESHEETAuthorsHillary Mennella, DNPBetseyCalderon89
 
HIVProjectProgressPoster[1]
HIVProjectProgressPoster[1]HIVProjectProgressPoster[1]
HIVProjectProgressPoster[1]Mary Beth Levin
 
Steven Heilman - mHealth in everyday practice
Steven Heilman - mHealth in everyday practiceSteven Heilman - mHealth in everyday practice
Steven Heilman - mHealth in everyday practicePlain Talk 2015
 
Genomics-health, Pharmacogenomics.pdf
Genomics-health, Pharmacogenomics.pdfGenomics-health, Pharmacogenomics.pdf
Genomics-health, Pharmacogenomics.pdfshinycthomas
 
Covid 19 vaccine conversations 2021 01-20
Covid 19 vaccine conversations 2021 01-20Covid 19 vaccine conversations 2021 01-20
Covid 19 vaccine conversations 2021 01-20CHC Connecticut
 
Dr. Lauri Hicks - One Health Antibiotic Stewardship Human Health Examples
Dr. Lauri Hicks - One Health Antibiotic Stewardship Human Health ExamplesDr. Lauri Hicks - One Health Antibiotic Stewardship Human Health Examples
Dr. Lauri Hicks - One Health Antibiotic Stewardship Human Health ExamplesJohn Blue
 
Η συνεισφορά της Γενικής Οικογενειακής Ιατρικής στη Φαρμακοεπιδημιολογία
Η συνεισφορά της Γενικής Οικογενειακής Ιατρικής στη ΦαρμακοεπιδημιολογίαΗ συνεισφορά της Γενικής Οικογενειακής Ιατρικής στη Φαρμακοεπιδημιολογία
Η συνεισφορά της Γενικής Οικογενειακής Ιατρικής στη ΦαρμακοεπιδημιολογίαEvangelos Fragkoulis
 

Similar to Updates on COVID-19 Research: SECURE-IBD & IBD Partners (20)

Covid 19 vaccination-isop_june_2021
Covid 19 vaccination-isop_june_2021Covid 19 vaccination-isop_june_2021
Covid 19 vaccination-isop_june_2021
 
Designing Causal Inference Studies Using Real-World Data
Designing Causal Inference Studies Using Real-World DataDesigning Causal Inference Studies Using Real-World Data
Designing Causal Inference Studies Using Real-World Data
 
CCSN Impact on Cancer Patients W4 Webinar June 23 2022.
CCSN Impact on Cancer Patients W4 Webinar June 23 2022.CCSN Impact on Cancer Patients W4 Webinar June 23 2022.
CCSN Impact on Cancer Patients W4 Webinar June 23 2022.
 
Determining Prognosis in Cancer and Non-Cancer Diagnosis
Determining Prognosis in Cancer and Non-Cancer DiagnosisDetermining Prognosis in Cancer and Non-Cancer Diagnosis
Determining Prognosis in Cancer and Non-Cancer Diagnosis
 
Adherence to Antiretroviral Therapy among HIVPositive Patients in Central Hos...
Adherence to Antiretroviral Therapy among HIVPositive Patients in Central Hos...Adherence to Antiretroviral Therapy among HIVPositive Patients in Central Hos...
Adherence to Antiretroviral Therapy among HIVPositive Patients in Central Hos...
 
Weitzman ECHO COVID-19: Caring for Key Populations
Weitzman ECHO COVID-19: Caring for Key PopulationsWeitzman ECHO COVID-19: Caring for Key Populations
Weitzman ECHO COVID-19: Caring for Key Populations
 
PPT PROJECT FINAL-1-1.pptx
PPT PROJECT FINAL-1-1.pptxPPT PROJECT FINAL-1-1.pptx
PPT PROJECT FINAL-1-1.pptx
 
HJS_HIVSurveyProject
HJS_HIVSurveyProjectHJS_HIVSurveyProject
HJS_HIVSurveyProject
 
EVIDENCE-BASED CARESHEETAuthorsHillary Mennella, DNP
EVIDENCE-BASED CARESHEETAuthorsHillary Mennella, DNPEVIDENCE-BASED CARESHEETAuthorsHillary Mennella, DNP
EVIDENCE-BASED CARESHEETAuthorsHillary Mennella, DNP
 
HIVProjectProgressPoster[1]
HIVProjectProgressPoster[1]HIVProjectProgressPoster[1]
HIVProjectProgressPoster[1]
 
Steven Heilman - mHealth in everyday practice
Steven Heilman - mHealth in everyday practiceSteven Heilman - mHealth in everyday practice
Steven Heilman - mHealth in everyday practice
 
Genomics-health, Pharmacogenomics.pdf
Genomics-health, Pharmacogenomics.pdfGenomics-health, Pharmacogenomics.pdf
Genomics-health, Pharmacogenomics.pdf
 
Early Age Onset (EAO) Working Meeting
Early Age Onset (EAO) Working MeetingEarly Age Onset (EAO) Working Meeting
Early Age Onset (EAO) Working Meeting
 
Covid 19 vaccine conversations 2021 01-20
Covid 19 vaccine conversations 2021 01-20Covid 19 vaccine conversations 2021 01-20
Covid 19 vaccine conversations 2021 01-20
 
San Diego Primary Care Providers' Attitudes to HIV and HIV Testing
San Diego Primary Care Providers' Attitudes to HIV and HIV TestingSan Diego Primary Care Providers' Attitudes to HIV and HIV Testing
San Diego Primary Care Providers' Attitudes to HIV and HIV Testing
 
Dr. Lauri Hicks - One Health Antibiotic Stewardship Human Health Examples
Dr. Lauri Hicks - One Health Antibiotic Stewardship Human Health ExamplesDr. Lauri Hicks - One Health Antibiotic Stewardship Human Health Examples
Dr. Lauri Hicks - One Health Antibiotic Stewardship Human Health Examples
 
FINAL POSTER
FINAL POSTERFINAL POSTER
FINAL POSTER
 
Η συνεισφορά της Γενικής Οικογενειακής Ιατρικής στη Φαρμακοεπιδημιολογία
Η συνεισφορά της Γενικής Οικογενειακής Ιατρικής στη ΦαρμακοεπιδημιολογίαΗ συνεισφορά της Γενικής Οικογενειακής Ιατρικής στη Φαρμακοεπιδημιολογία
Η συνεισφορά της Γενικής Οικογενειακής Ιατρικής στη Φαρμακοεπιδημιολογία
 
Patient-Centered Pharmacovigilance
Patient-Centered Pharmacovigilance Patient-Centered Pharmacovigilance
Patient-Centered Pharmacovigilance
 
The challenges of zika: a health IT response
The challenges of zika: a health IT responseThe challenges of zika: a health IT response
The challenges of zika: a health IT response
 

Recently uploaded

SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxdrashraf369
 
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityCEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityHarshChauhan475104
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners
 
Prince Paulraj W HERBAL DRUG TECHNO.pptx
Prince Paulraj W HERBAL DRUG TECHNO.pptxPrince Paulraj W HERBAL DRUG TECHNO.pptx
Prince Paulraj W HERBAL DRUG TECHNO.pptxprincebieber28
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptxBibekananda shah
 
Systemic Lupus Erythematosus -SLE PT2.ppt
Systemic  Lupus  Erythematosus -SLE PT2.pptSystemic  Lupus  Erythematosus -SLE PT2.ppt
Systemic Lupus Erythematosus -SLE PT2.pptraviapr7
 
Nutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience ClassNutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience Classmanuelazg2001
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfDivya Kanojiya
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdfDolisha Warbi
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdfDolisha Warbi
 
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdfSGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdfHongBiThi1
 
Role of medicinal and aromatic plants in national economy PDF.pdf
Role of medicinal and aromatic plants in national economy PDF.pdfRole of medicinal and aromatic plants in national economy PDF.pdf
Role of medicinal and aromatic plants in national economy PDF.pdfDivya Kanojiya
 
Giftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-KnowledgeGiftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-Knowledgeassessoriafabianodea
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurNavdeep Kaur
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiGoogle
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxKezaiah S
 
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)MohamadAlhes
 
Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!ibtesaam huma
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...sdateam0
 

Recently uploaded (20)

SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
 
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityCEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
 
Prince Paulraj W HERBAL DRUG TECHNO.pptx
Prince Paulraj W HERBAL DRUG TECHNO.pptxPrince Paulraj W HERBAL DRUG TECHNO.pptx
Prince Paulraj W HERBAL DRUG TECHNO.pptx
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
 
Systemic Lupus Erythematosus -SLE PT2.ppt
Systemic  Lupus  Erythematosus -SLE PT2.pptSystemic  Lupus  Erythematosus -SLE PT2.ppt
Systemic Lupus Erythematosus -SLE PT2.ppt
 
Nutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience ClassNutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience Class
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdf
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
 
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdfSGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
 
Role of medicinal and aromatic plants in national economy PDF.pdf
Role of medicinal and aromatic plants in national economy PDF.pdfRole of medicinal and aromatic plants in national economy PDF.pdf
Role of medicinal and aromatic plants in national economy PDF.pdf
 
Giftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-KnowledgeGiftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-Knowledge
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali Rai
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptx
 
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
 
Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
 
JANGAMA VISHA .pptx-
JANGAMA VISHA .pptx-JANGAMA VISHA .pptx-
JANGAMA VISHA .pptx-
 

Updates on COVID-19 Research: SECURE-IBD & IBD Partners

  • 1. Welcome Brent Polk, MD SECURE-IBD REGISTRY AND IBD PARTNERS UPDATE Data pulled on 5/21/2020. Updated data from SECURE-IBD can be viewed at covidibd.org. Additional information on IBD Partners is available at ccfa.med.unc.edu
  • 2. Michael Kappelman MD, MPH (University of North Carolina at Chapel Hill) Erica Brenner, MD (University of North Carolina at Chapel Hill) Jean-Frederic Colombel, MD (Icahn School of Medicine at Mount Sinai, New York) Ryan Ungaro, MD MS (Icahn School of Medicine at Mount Sinai, New York)
  • 3. Purpose • To rapidly define the impact of coronavirus on patients with IBD and evaluate how factors such as age, comorbidities, and IBD treatments affect coronavirus outcomes. • To openly share findings with the IBD community including the outcomes of COVID-19 broken down by patient age, gender, IBD treatments, and other factors.
  • 4. Database • Web-based survey filled out by IBD health care providers from across the globe – Collects data on patient location, demographics, IBD characteristics, comorbidities, and coronavirus outcomes • Data stored on secure, encrypted servers at the University of North Carolina • All data are de-identified, in accordance with HIPAA Safe Harbor standards
  • 5. Website • Landing page • Project information and FAQs • Access to the database • Facilitate rapid sharing of data • Link to patient/provider resources • Acknowledge partnering organizations
  • 6. Why is the registry important for patients? • SECURE-IBD will help answer important questions about coronavirus risk for patients with IBD, particularly regarding IBD medications and characteristics • The online format allows for rapid and free data sharing
  • 7. • 1170 reported cases • 42 different countries • Median age 45 • 52% Male • 56% Crohn’s disease Preliminary data (5/18/20)
  • 13. SECURE-IBD Take Away Points • Overall low mortality ~ 4% – No deaths in patients <20 years of age • Systemic steroids appear to be a risk factor for worse outcomes of COVID-19 • Anti-TNF biologic therapy appears to be safe • Need more data and further analyses to fully evaluate safety of other classes of medications • In general, data support current recommendations to continue IBD therapy in healthy patients – Discuss with physician temporary holding of medications for infected pts
  • 14. Our Partners: Thank you! And many more organizations and pharmaceutical partners listed at https://covidibd.org/our-partners/ SECURE-IBD has been funded, in part, by the Helmsley Charitable Trust, multi-pharmaceutical sponsorship, and NC TraCS
  • 15. COVID-19 and Inflammatory Bowel Disease: IBD Partners Patient Powered Research Network Millie D. Long MD, MPH 5-20-2020 Associate Professor of Medicine Vice-Chief for Education Director, Gastroenterology and Hepatology Fellowship Program Inflammatory Bowel Diseases Center University of North Carolina-Chapel Hill
  • 16. What is IBD Partners? • Large, diverse population Follow natural history of disease • Exposures, health behaviors, outcomes Patient generated data • Surveys, health apps/devices, personal health records Include diverse data sources • Support a diverse array of studies Create widely-used resource • Goal of improving outcomes Increase patient partners/ citizen scientists Long MD, et al. Inflamm Bowel Dis. 2012 Nov;18(11):2099-106.
  • 17. Who we are: Partners IBD Patient Community Crohn’s & Colitis Foundation Researchers/ UNC Data Management Center Long MD, et al. Inflamm Bowel Dis. 2012 Nov;18(11):2099-106.
  • 18. IBD Partners represents the future of IBD research • A partnership with patients • Internet increases participation and potentially allow previously under-represented groups to be included • Ability to study those questions that matter the most to patients • Collaborative and open-access research with diverse groups of investigators participating – including academic faculty, trainees, industry and patients • Thus far over 50 researchers from various institutions across the country have participated in IBD Partners research • Collaborations with federal funding agencies • Collaborations with industry funding for investigator initiated projects on real world data, which is increasing recognized by the FDA • Opportunity for large scale RCTS of modifiable factors in IBD based on data from prospective cohorts
  • 19. How it works • Enroll IBD patients from Foundation email rosters, Foundation web-page link, social media, walks, clinics, etc. • Baseline survey – Demographics, disease characteristics, medications, family history, quality of life scales – Disease activity instruments • Follow-up surveys - change in treatment or health status – Medications, surgery, disease activity – Addition of modules - pain, fatigue, sleep, physical function, emotional distress, social support • Short data collection through portal, can be daily • Syncing apps to make use of existing “big data” resources
  • 20. Current IBD Partners Enrollment (>15,000!)
  • 21. How it works: Patients Pose Questions Influence IBD research by proposing, discussing, and voting on research questions. Examples of questions proposed by patients: • “We should compare individuals who manage their disease with medication and those who manage their disease with popular diets in the IBD community, such as SCD, FODMAPS, paleo, etc.” • “Research the validity of VSL#3 probiotic in controlling flare ups or as a factor in remission.” • “What is the role of stress and the stress response in autoimmunity?” • “Compare symptoms of IBD patients who consume dairy and those who avoid dairy.” • How is COVID-19 affecting IBD Patients? What are the risks of COVID-19 for IBD Patients?
  • 22. COVID-19 Survey in IBD Partners • Questions on symptoms, diagnosis, testing for COVID-19 for each patient, as well as levels of general knowledge about resources in their area (testing, etc.) • Collect data on medication use, disease activity • Understand health care utilization – access to telemedicine, issues with obtaining medications, refills, getting to infusions, etc • Understand level of concern in IBD patients, both for developing COVID-19 and concerns surrounding particular medications • Understand loss of employment, insurance due to COVID-19 • Track real time cases in states throughout the US Goal: Report this information back to patients, in summaries and maps available on the IBD Partners Website
  • 23. Characteristics of patients (n=1439) N (Mean) % (SD) Median IQR Total number of patients 1439 Age (years) 49.7 15.15 49 37.0 ,62.0 Gender (% female) 1050 74.7% 0 Education (% >high school) 1308 90.9% Race (%) Caucasian 1269 88.2% African American 19 1.3% Other 151 10.5% Current smoking (% yes) 31 2.2% BMI 26.0 6.03 24.5 21.9 ,28.7 Disease duration (years) 21.1 13.01 18 12.0 ,28.0 Ever GI surgery (% yes) 649 46.1% Ever GI hospitalization (% yes) 914 65.0% Number hospitalizations 3.7 2.65 3 1.0 ,6.0 Current medications (%) Biologic Anti-TNF 497 35.4% Immunomodulator* 307 21.8% Corticosteroids 110 7.8% 5-ASA 397 28.2% Remission (sCDAI^ <150 or SCCAI ≤2) (% yes) 729 68.7% sCDAI (median, IQR) 127.0 85.30 107 58.0 ,163.0 SCCAI (median, IQR) 2.1 1.99 2 1.0 ,3.0 Anxiety (PROMIS T score) 51.4 9.46 51.2 40.3 ,57.7
  • 24. Level of Concern about COVID How concerned are you about COVID? How concerned are you that your medications increase your COVID risk?
  • 27. Telehealth and Information Sources for Patients • 78.5% of IBD patients’ doctors offices are offering telehealth • 42% of patients have had a telehealth visit • Where are patients getting data about COVID-19? – GI physicians (36.7%) – CDC 78.4% – News 88.0% – Social media 37.2% – Crohns and Colitis Foundation website 38.1% – Other websites 25.9% – Family/friends 34.1% – Other 7.5%
  • 28. Employment Status and Health Insurance Loss Due to COVID-19 • Employment change due to COVID-19 – Laid off 4.7% – Reduced hours 9.0% – Work from home now 39.0% – Changed jobs 0.3% – Job responsibilities changed 6.9% • Health insurance change – Lost insurance 0.2% – Change in insurance 0.4% – Other 0.5%
  • 29. Patients Reporting Sickness (n=557) • 557 patients (38.7%) report becoming sick • 62 patients (4.3%) tested • 44 patients (3.1%) were in contact with someone who tested positive • 7 patients (0.5%) with COVID-19 confirmed by testing • 54 patients (3.8%) stopped a IBD medication when they were sick • Severity of illness among those who were sick – Very mild 106 patients, 19% – Mild 200 patients, 36% – Moderate 212 patients, 38% – Severe 34 patients, 6% – Very severe 3 patients, 1%
  • 30. Interactive Map of Sickness and COVID+ in the US for IBD Patients
  • 31. Medication Changes Among Those NOT Sick (n=880) • Have you temporarily stopped medications due to concerns for COVID-19? – 37 patients, 4% • Why did you stop the medication? – Doctor told me to (38%) – I thought it would reduce my chances of COVID (92%) – I thought it would make COVID infection worse (81%) – Other (54%)
  • 32. Summary • IBD patients are extremely concerned about COVID-19 risks generally and medication-specific risks • Patients are avoiding many health-related activities like labs, procedures and even infusions • Nearly all IBD patients in this survey are self-isolating • Less than ½ of IBD patients have accessed telehealth • Many patients have had work-related changes, particularly working from home, although a minority have been laid off; majority have retained health insurance • Many patients report sickness symptoms, only a small minority have been tested • Some patients (~4%) have stopped medications due to concerns for COVID-19 • Continued surveys will allow us to track rates real-time across the country to better inform the IBD community
  • 34. Thank you to our sponsors: 34 Additional support is provided through the Foundation’s annual giving program and donors.
  • 35. Learn more @ cctakesteps.org Unite with the IBD community at our first virtual walk! Saturday, June 20, 2020 12:00PM to 3:00PM (ET)